Phase II
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
This morning, the Indianapolis-based company said it will delay most new study starts and pause enrollment in most ongoing studies in light of the COVID-19 pandemic.
The company said the decision to advance the CGRP receptor antagonist into late-stage studies followed a successful end-of-phase meeting with the U.S. Food and Drug Administration.
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
PRESS RELEASES